TITLE

Patient reported outcomes as endpoints in medical research

AUTHOR(S)
Fairclough, Diane L.
PUB. DATE
April 2004
SOURCE
Statistical Methods in Medical Research;Apr2004, Vol. 13 Issue 2, p115
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This review covers a number of the many design and analytic issues associated with clinical trials that incorporate patient reported outcomes as primary or secondary endpoints. We use a clinical trial designed to evaluate a new therapy for the prevention of migraines to illustrate how endpoints are defined by the objectives of the study, the methods for handling longitudinal assessments with multiple scales or outcomes, and the methods of analysis in the presence of missing data.
ACCESSION #
12916783

 

Related Articles

  • Fully informed consent is impossible in surgical clinical trials. Bernstein, Mark // Canadian Journal of Surgery;Aug2005, Vol. 48 Issue 4, p271 

    This article reports that fully informed consent by patient is impossible in surgical clinical trials. Consent for an investigative procedure has 3 distinct but interrelated elements that are essentially the same as for purely therapeutic procedures: disclosure, capacity and voluntariness. It is...

  • Competing Interests. Carroll-Johnson, Rose Mary // Oncology Nursing Forum;May/Jun2004, Vol. 31 Issue 3, p483 

    Explores a variety of issues concerning clinical research. Factors relevant to clinical research; Role of registered nurses in clinical research implementation; Advantages of patients participating in clinical trials.

  • Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials. Yusuf, Salim; Wittes, Janet; Probstfield, Jeffrey; Tyroler, Herman A. // JAMA: Journal of the American Medical Association;7/3/91, Vol. 266 Issue 1, p93 

    Discusses common drawbacks associated with analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Purpose of subgroup analysis; Comparison between proper and improper subgroups; Recommendations.

  • Teriparatide weakens alendronic acid's case in osteoporosis.  // Reactions Weekly;12/1/2007, Issue 1180, p1 

    The article discusses the results of a clinical trial on the effectivity of teriparitide in patients with glucocorticoid-induced osteoporosis. It found that a significantly greater increase from baseline in bone mineral density at the lumbar spine was observed for the teriparatide group compared...

  • DETERMINING PATIENTS' WILLINGNESS TOWARDS CLINICAL TRIAL PARTICIPATION IN A PSYCHIATRIC HOSPITAL. Sim, Esther; Wong Hung Chew // Singapore Nursing Journal;Oct-Dec2005, Vol. 32 Issue 4, p12 

    A retrospective non-experimental descriptive study on 100 outpatient patients was done in a Singapore psychiatric hospital to determine their willingness towards clinical trial participation. The instruments used were Drug Attitude Inventory-10, Rating Scale for Side Effects, SF-12 and...

  • The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Jenkins, V.; Farewell, D.; Batt, L.; Maughan, T.; Branston, L.; Langridge, C.; Parlour, L.; Farewell, V.; Fallowfield, L. // British Journal of Cancer;12/7/2010, Vol. 103 Issue 12, p1801 

    Background: barriers to randomised clinical trial (RCT) recruitment include failure to identify eligible patients, reluctance of staff to approach them and attitudes of some health-care professionals and patients. As part of a larger UK prospective study examining the communication...

  • CHR to develop therapeutic clinical trial of liberation therapy for multiple sclerosis. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, pE793 

    The article reports that the Canadian Institutes of Health Research (CIHR) plans to develop a Phase I/II interventional trial on the therapeutic validity of balloon venoplasty for multiple sclerosis (MS). It states that the trial seeks to ensure accurate and standardized identification of MS...

  • Is It Possible to Blind a Trial for Community- Acquired Pneumonia? Boucher, Helen W. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS210 

    Blinding a randomized, controlled clinical trial provides benefits on several levels but often is not perfectly executed or well described. Most recent registration trials of therapy for community-acquired pneumonia were designed and conducted as blinded trials, although the descriptions of...

  • Historical and Regulatory Perspectives on the Treatment Effect of Antibacterial Drugs for Community-Acquired Pneumonia. Singer, M.; Nambiar, S.; Valappil, T.; Higgins, K.; Gitterman, S. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS216 

    A noninferiority margin based on the treatment effect of antibacterial drugs is required for noninferiority studies of community-acquired pneumonia. A quantitative estimate of treatment effect is generally determined from placebo-controlled trials, but, since the mid-to-late 1930s, no studies...

  • Deconstruction of Nurse-Delivered Patient Self-Management Interventions for Symptom Management: Factors Related to Delivery Enactment and Response. Given, Charles W.; Given, Barbara A.; Sikorskii, Alla; Mei You; Jeon, Sangchoon; Champion, Victoria; McCorkle, Ruth // Annals of Behavioral Medicine;Aug2010, Vol. 40 Issue 1, p99 

    This research examines the processes by which patient self-management interventions are related to symptom responses among cancer patients. A total of 333 patients from two randomized clinical trials were combined. Each patient received a six-contact 8-week patient self-management intervention...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics